Logo
Logo


ISSN: 0300-9041
ISSNe: 2594-2034


Indizada en: SciELO, Índice Médico Latinoamericano, LILACS, Medline
Editada por la Federación Mexicana de Colegios de Obstetricia, y Ginecologia AC
Fundada por la Asociación Mexicana de Ginecología y Obstetricia en 1945
 

INFORMACIÓN EXCLUSIVA PARA LOS PROFESIONALES DE LA SALUD


Periodicidad: continua
Abreviatura: Ginecol Obstet Mex
ISSN: 0300-9041
ISSNe: 2594-2034
Indizada en: Scimago, Índice Médico Latinoamericano, Lilacs, Medline, Science Citation Index, Ulrich, Ebsco.

Teratoma quístico maduro con transformación maligna: serie de casos

Cystic teratoma with malignant transformation: Series of cases.

Ginecol Obstet Mex. 2020 marzo;88(3):154-160.

https://doi.org/10.24245/gom.v88i3.3561

Víctor Edmundo Valdespino-Castillo,1 Germán Maytorena-Córdova,2 Israel López-Matamoros,3 Juan Landa-Mejía,3 Perla Esther Zaragoza-Vargas,4 Víctor Manuel Valdespino-Gómez5

1 Cirujano oncólogo.
2 Jefe del servicio de Oncología.
3 Residente de Oncología ginecológica.
4 Patóloga.
5 Academia Mexicana de Cirugía.
Unidad Médica de Alta Especialidad, Hospital de Ginecología y Obstetricia 4 Luis Castelazo Ayala, IMSS, Ciudad de México.


Corrrespondencia:

Víctor Edmundo Valdespino Castillo
edvaldespinocg@yahoo.com

Debe citarse como:

Valdespino-Castillo VE, Maytorena-Córdova G, López-Matamoros I, Landa-Mejía J, Zaragoza-Vargas PE, Valdespino-Gómez V. Teratoma quístico maduro con transformación maligna: serie de casos. Ginecol Obstet Mex. 2020 marzo;88(3):154-160. https://doi.org/10.24245/gom.v88i3.3561

Resumen

OBJETIVO: Describir las características clínicas e histopatológicas de los casos de teratoma maduro con transformación maligna, su tratamiento y supervivencia.

MATERIALES Y MÉTODOS: Estudio retrospectivo, transversal y observacional efectuado entre enero de 2014 y diciembre de 2018 en un servicio de oncología ginecológica. Parámetros de estudio: etapa patológica del tumor, concentraciones de Ca 125, supervivencia y tratamiento. El tamaño de la muestra no permitió aplicar pruebas estadísticas.

RESULTADOS: Se estudiaron 147 pacientes con diagnóstico de teratoma maduro, de éstos 4 experimentaron transformación maligna a carcinoma epidermoide y se descartaron 18 por información incompleta. El estudio histopatológico transoperatorio identificó malignidad en 3 de los 4 tumores de ovario. No se practicaron cirugías conservadoras de la fertilidad porque en ninguno de los casos fue necesaria. En 3 de los 4 teratomas maduros con transformación maligna se indicó esquema de quimioterapia coadyuvante. Todas las pacientes permanecen vivas y sin recaída hasta el momento.

CONCLUSIONES: El estudio histopatológico transoperatorio es indispensable en todas las lesiones de ovario, incluso las de aspecto quístico. El tratamiento quirúrgico cuidadoso de los tumores malignos de ovario evita su ruptura y cambio en el pronóstico y tratamiento de las pacientes. El tratamiento quirúrgico y médico de una neoplasia poco frecuente, como el teratoma maduro con transformación maligna, mejora la supervivencia y evita subtratamientos o sobretratamientos.

PALABRAS CLAVE: Teratoma maduro; carcinoma de células escamosas; tumores de ovario; quimioterapia coadyuvante; sobretratamiento; tamaño de la muestra.

Abstract

OBJECTIVE: Describe the clinical and histopathological characteristics of cases of mature teratoma with malignant transformation, its treatment and survival.

MATERIALS AND METHODS: Retrospective, cross-sectional and observational study conducted between January 2014 and December 2018 in a gynecological oncology service. Study parameters: pathological stage of the tumor, concentrations of Ca 125, survival and treatment. The sample size did not allow statistical tests to be applied.

RESULTS: 147 patients with a diagnosis of mature teratoma were studied of these 4 underwent malignant transformation to squamous cell carcinoma and 18 were ruled out due to incomplete information. The transoperative histopathological study identified 3 of the 4 ovarian tumors as malignant. Fertility conservative surgeries were not performed because in none of the cases was it necessary. In 3 of the 4 mature teratomas with malignant transformation, adjuvant chemotherapy scheme was indicated. All patients remain alive and have no relapse so far.

CONCLUSIONS: The histopathological transoperatory study is absolutely necessary for an ovarian tumor, even in cystic ovarian tumors. Carefully management of ovarian tumors is very important, we should prevent a rupture of the malignant tumor because this changes the surgical stage and the prognosis. The surgical and medical treatment of infrequent tumor-like mature teratoma with malignant transformation improves survival and avoid sub treatments or overtreatment.

KEYWORDS: Mature teratoma; Sample size; Squamous cell carcinoma; Ovarian tumors; Adjuvant chemotherapy; Overtreatment.

    1. Li C, et al. Squamous cell carcinoma transformation in mature cystic teratoma of the ovary: a systematic review. BMC Cancer 2019; 19: 217. https://doi.org/10.1186/s12885-019-5393-y
    2. Cheung AH, et al. Mismatch repair deficiency is implicated in carcinoma arising from ovarian teratoma. Pathology 2019; 51: 67-73. https://doi.org/10.1016/j.pathol.2018.09.061
    3. Kurt S, et al. Effects of mature cystic teratoma on reproductive health and malignant transformation: A retrospective analysis of 80 cases. Journal of the Turkish German Gynecological Association, 20(2), 84–88. https://doi.org/10.4274/jtgga.galenos.2018.2018.0003
    4. Black JD, et al A series of malignant ovarian cancers arising from within a mature cystic teratoma: a single institution experience. Int J Gynecol Cancer 2015; 25: 792-97. http://dx.doi.org/10.1097/IGC.0000000000000431
    5. Van Calster B, et al. Practical guidance for applying the ADNEX model from the IOTA group to discriminate between different subtypes of adnexal tumors. Facts Views Vis Obgyn 2015; 7: 32-41. PMC4402441
    6. Dorado RE, Carrillo GO. Transformación maligna de un teratoma quístico maduro de ovario: reporte de un caso. Ginecol Obstet Mex 2017; 85: 862-867. https://doi.org/10.24245/gom.v85i12.1643
    7. Hanada M, et al. Multiple malignancies (squamous cell carcinoma and sarcoma) arising in a dermoid cyst of the ovary. Pathol Int 1981; 31: 681-88. https://doi.org/10.1111/j.1440-1827.1981.tb02763.x
    8. Davis GL. Malignant melanoma arising in mature ovarian cystic teratoma (dermoid cyst). Report of Two cases and literature analysis. Int J Gynecol Pathol 1996; 15: 356-62. doi: 10.1097/00004347-199610000-00009
    9. Kikkawa F, et al. Diagnosis of squamous cell carcinoma arising from mature cystic teratoma of the ovary. Cancer 1998; 82: 2249-55. https://doi.org/10.1002/(SICI)1097-0142(19980601)82:11<2249::AID-CNCR21>3.0.CO;2-T
    10. Li C, et al. Squamous cell carcinoma transformation in matura cystic teratoma of the ovary: a systematic review. BMC Cancer 2019; 19: 217. https://doi.org/10.1186/s12885-019-5393-y
    11. Kyeong HK, et al. A rare case of squamous cell carcinoma in situ arising in mature cystic teratoma. Obstet Gynecol Sci 2018; 61: 631-35. https://doi.org/10.5468/ogs.2018.61.5.631
    12. Dos Santos L, et al. Squamous cell carcinoma arising in mature cystic teratoma of the ovary: a case series and review of the literature. Gynecol Oncol 2007; 105: 321-24. https://doi.org/10.1016/j.ygyno.2006.12.008
    13. Park JY, et al. Malignant transformation of mature cystic teratoma of the ovary: experience at a single institution. Eur J Obstet Gynecol Reprod Biol 2008; 141: 173-78. https://doi.org/10.1016/j.ejogrb.2008.07.032
    14. Hirakawa T, et al. Squamous cell carcinoma arising in mature cystic teratoma of the ovary. Clinicopathologic and topographic analysis. Am J Surg Pathl 1989; 13: 397-405. doi: 10.1097/00000478-198905000-00007
    15. Sakuma M, et al. Malignant transformation arising from mature cystic teratoma of the ovary: a retrospective study of 20 cases. Int J Gynecol Cancer 2010; 20: 766-71. doi: 10.1111/igc.0b013e3181daaf1d
    16. Gadducci A, et al. Squamous cell carcinoma arising from mature cystic teratoma of the ovary: A challenging question for gynecologic oncologists. Crit Rev Oncol Hematol 2019; 133: 92-98. https://doi.org/10.1016/j.critrevonc.2018.10.005
    17. Yoshikawa N, et al. Fertility-sparing surgery of malignant transformation arising from mature cystic teratoma of the ovary. Oncotarget 2018; 44: 27564-73. doi: 10.18632/oncotarget.25548.
    18. Araujo I, et al. High frequency of malignant transformation of ovarian mature teratoma into squamous cell carcinoma in young patients in northeast Brazil. Int Jour Gynecol Pathol 2016; 35: 176-84. doi: 10.1097/PGP.0000000000000225.
    19. Tato-Varela S, et al. Impact of retroperitoneal lymph node dissection in ovarian cancer-time for paradigm shift? Horm Mol Biol Clin Investig 2019. doi: 10.1515/hmbci-2019-0020.
    20. Heitz F, et al. Stage- and Histologic Subtype-Dependent Frequency of Lymph Node Metastases in Patients with Epithelial Ovarian Cancer Undergoing Systematic Pelvic and Paraaortic Lymphadenectomy. Ann Surg Oncol 2018; 25 (7): 2053-59. https://doi.org/10.1245/s10434-018-6412-y

Comentarios